PN-152,243
Hodgkin Disease
PfizerPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
150 Active assets in the Hodgkin Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Fred Hutchinson Cancer Center | Phase 3 | BBB |
CYCLOSPORIN A City of Hope Medical Center | Phase 3 | BBB |
Carboplatin St. Petersburg State Pavlov Medical University | Phase 2 | BBB |
Cytosin-Arabinosid Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BBB |
Everolimus OHSU Knight Cancer Institute | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
PN-152,243 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →